Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
- Reuters
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer ou...
FDA lifts partial hold on MediLink Therapeutics' phase 1 trial for HER3-targeting ADC BNT326/YL202 in advanced lung and bre...
HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of...
The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite o...
JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Underweight and lowers the price target from $94 to $91.
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The ...
